Research programme: biosimilars - Biocon/Sandoz

Next Previous
Drug Profile

Research programme: biosimilars - Biocon/Sandoz

Alternative Names: Immunology biologics - Biocon/Sandoz; Next-generation biosimilars - Biocon/Sandoz; Oncology biologics - Biocon/Sandoz

Latest Information Update: 23 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocon; Sandoz
  • Class Antineoplastics; Biological factors; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Immunological disorders

Most Recent Events

  • 18 Jan 2018 Sandoz and Biocon enter into an exclusive global collaboration to develop, manufacture and commercialise multiple biosimilars for Immunological disorders and Cancer
  • 18 Jan 2018 Early research in Cancer in Germany, India (Parenteral)
  • 18 Jan 2018 Early research in Immunological disorders in Germany, India (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top